XSHE
300401
Market cap1.38bUSD
Jul 10, Last price
16.56CNY
1D
-1.10%
1Q
20.96%
Jan 2017
12.85%
IPO
672.07%
Name
Zhejiang Garden Biopharmaceutical Co Ltd
Chart & Performance
P/E
29.59
P/S
7.29
EPS
0.56
Div Yield, %
0.67%
Shrs. gr., 5y
1.93%
Rev. gr., 5y
13.41%
Revenues
1.24b
-0.47%
Net income
305m
-1.41%
CFO
475m
+1.79%
Dividend
Apr 30, 20250.114 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Garden Biopharmaceutical Co.,Ltd. operates as a food additive and pharmaceutical manufacturing industry in China. The company provides lanolin cholesterol, vitamin A and AD3 particles, vitamin D3, 25-hydroxyvitamin D3, chemical drugs and Chinese patent medicines. It offers cholesterol; feed grade vitamin D3, refined lanolin; food additives compound nutrient fortifier SDS, CO, and MO; cholecalciferol; feed additive - vitamin D3 particles and oil; VD3 resin oil; 25 hydroxyvitamin D3 progen and powder; 25 hydroxyvitamin D3; anhydrous lanolin; wood oil; wool wax; low chroma pure fat; lanolin alcohol; isopropyl lanolate; lanolinic acid; high acid fat; wood acid biofuel/wood alcohol biofuel; and rodenticide made from Vitamin D3. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||